Supportive Care in Cancer

, Volume 5, Issue 5, pp 358–364

Controversies in new antibiotic therapy for ambulatory patients

Authors

  • V. Sundararajan
    • Ambulatory and Supportive Care Oncology Research Program (ASCORP), The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
  • Edward B. Rubenstein
    • Ambulatory and Supportive Care Oncology Research Program (ASCORP), The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
  • Kenneth V. I. Rolston
    • Ambulatory and Supportive Care Oncology Research Program (ASCORP), The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
  • Linda S. Elting
    • Ambulatory and Supportive Care Oncology Research Program (ASCORP), The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
REVIEW ARTICLE

DOI: 10.1007/s005200050092

Cite this article as:
Sundararajan, V., Rubenstein, E., Rolston, K. et al. Support Care Cancer (1997) 5: 358. doi:10.1007/s005200050092

Abstract

 The care of the febrile neutropenic patient has undergone a shift in the last 10 years with the realization that neutropenic patients presenting with fever do not constitute a homogeneous group. Strategies of risk assessment have allowed the testing of novel therapies including oupatient treatment with oral and intravenous antibiotics, either in combination regimens or as monotherapy; the addition of growth factors to hasten the return of the absolute neutrophil count; and the possibility of self-initiation of antibiotics by cancer patients when they develop fever. The clinical trials data regarding these new approaches will be reviewed, and areas requiring further research will be discussed.

Key words NeutropeniaFeverAntibioticsClinical trials
Download to read the full article text

Copyright information

© Springer-Verlag Berlin Heidelberg 1997